Hypersensitivity to aspirin is rare disorder occurring in 1.88% of the patients. Aspirin-hypersensitive patients requiring single antiplatelet agent may be treated with clopidogrel, an alternative antiplatelet agent. However, aspirin desensitization is more cost-effective than the usage of clopidogrel in these patients. Furthermore, aspirin desensitization is of greater value in patients requiring dual antiplatelet therapy, for example following procedures like percutaneous transluminal coronary angioplasty (PTCA) instead of using non-aspirin-based combinations. Herein, we report a 74-year-old hypertensive male presented with features of acute coronary syndrome and planned for percutaneous transluminal coronary angioplasty of RCA followed by dual antiplatelet therapy. Since he had aspirin allergy, desensitization was done using rapid desensitization protocol for which he responded well. This case highlights the importance of aspirin-desensitization in patients with aspirin allergy instead of choosing non-aspirin based antiplatelet agents.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11455631PMC
http://dx.doi.org/10.31729/jnma.8643DOI Listing

Publication Analysis

Top Keywords

aspirin desensitization
12
acute coronary
8
coronary syndrome
8
patients requiring
8
antiplatelet agent
8
patients aspirin
8
dual antiplatelet
8
antiplatelet therapy
8
percutaneous transluminal
8
transluminal coronary
8

Similar Publications

Update on aspirin exacerbated respiratory disease with chronic rhinosinusitis.

Curr Opin Allergy Clin Immunol

December 2024

Ellsworth and Mabel Simmons Professor of Allergy and Immunology, Section Chief, Allergy/Immunology James A. Haley VA Hospital, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA.

Purpose Of Review: This review provides the current understanding on the mechanism, diagnosis, and treatment of aspirin exacerbated respiratory disease (AERD) with chronic rhinosinusitis (CRS).

Recent Findings: Updates focus on the current understanding of type 2 inflammation as a disease driver, alterations in gene expression in nasal polyps, and use of biologics in treating aspirin exacerbated respiratory disease. Recent findings include altered expression of GATA binding protein 3 (GATA3), interleukin (IL)-4, IL-5, and IL-17 in nasal polyps supports the current understanding that type 2 inflammation predominantly drives the pathophysiology of AERD with CRS.

View Article and Find Full Text PDF

Social factors associated with aspirin desensitization and diagnosis age in aspirin-exacerbated respiratory disease.

Int Forum Allergy Rhinol

November 2024

Department of Otorhinolaryngology, Head and Neck Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Article Synopsis
  • - Racial disparities affect the age at which individuals complete aspirin desensitization and receive a diagnosis for ASA-exacerbated respiratory disease (AERD).
  • - Having public insurance is linked to receiving an official AERD diagnosis after the age of 50.
  • - Social factors, such as race and insurance status, play a significant role in AERD diagnosis and the ability to adhere to aspirin desensitization protocols.
View Article and Find Full Text PDF

Fast-Track Aspirin Odyssey: ICU Chronicles.

Cureus

September 2024

Internal Medicine, Monmouth Medical Center, Rutgers University, Long Branch, USA.

Aspirin is used in patients with coronary artery disease essential in both acute and chronic phases of treatment, especially post-catheterization and post-coronary artery stent placement. Some patients have sensitivity to aspirin. Hypersensitivity reaction symptoms include itchy and watery eyes, itchy rash, worsening asthma, wheezing to fatal angioedema, and anaphylaxis.

View Article and Find Full Text PDF

Acetylsalicylic acid (ASA) represents a cornerstone of antiplatelet therapy for the treatment of atherosclerotic coronary artery disease (CAD). ASA is in fact indicated in case of an acute coronary syndrome or after a percutaneous coronary intervention with stent implantation. Aspirin hypersensitivity is frequently reported by patients, and this challenging situation requires a careful evaluation of the true nature of the presumed sensitivity and of its mechanisms, as well as to differentiate it from a more frequent (and more easily manageable) aspirin intolerance.

View Article and Find Full Text PDF
Article Synopsis
  • Low-dose aspirin is the most widely used antiplatelet medication for patients with atherosclerotic cardiovascular disease, but 1-5% of these patients experience aspirin hypersensitivity.
  • There is often confusion between aspirin hypersensitivity and intolerance, leading to unclear treatment guidelines and underutilization of desensitization techniques.
  • The text discusses the mechanisms of aspirin hypersensitivity and proposes alternative strategies and algorithms for managing patients who need aspirin therapy but can't tolerate it.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!